A boundary dance of amyloid-β stepping into dementia

Formation mechanism of the causative substances of Alzheimer’s disease revealed by molecular dynamics simulations and NMR experiments

Credit: ExCELLS/IMS

Many proteins aggregate at higher concentrations and form spherical substances called oligomers and acicular substances called amyloid fibrils. These protein aggregates cause more than 30 kinds of diseases, for example, Alzheimer’s disease is thought to be caused by the oligomers and amyloid fibrils formed by aggregation of amyloid-β (Aβ) peptides. It is known that aggregation of Aβ peptide is accelerated at a hydrophilic/hydrophobic interface such as a cell membrane surface. However, why the Aβ peptides tend to aggregate on the surface has not yet been well understood.

The research group at Exploratory Research Center on Life and Living Systems and Institute for Molecular Science, Japan worked on this problem using molecular dynamics simulations and nuclear magnetic resonance spectroscopy experiments. They found that the Aβ peptides tend to gather at the hydrophilic/hydrophobic interface. That is, the local concentration of Aβ at the interface is higher than that in bulk water solution. In addition, β-hairpin structures are formed more at the interface than in the bulk water solution. In the β-hairpin structure, as shown in the figure, a part of the Aβ peptide extends straight and forms intramolecular hydrogen bonds. Therefore, another Aβ peptide that comes close to this peptide is easy to make intermolecular hydrogen bonds and tends to aggregate. In this way, the research group clarified that the reason for accelerating the aggregation of the Aβ peptides on the cell membrane surface is that not only the Aβ peptide tends to have high concentration on the cell membrane surface but also it takes a structure that tends to bind to each other.

This discovery enables us to elucidate the mechanism by which the Aβ peptide aggregates on the membrane surface of nerve cells. Elucidating this mechanism will be applied to developing inhibitors against the causative substances of Alzheimer’s disease in the future.

###

Media Contact
Hisashi Okumura
[email protected]
81-564-557-277

Related Journal Article

http://dx.doi.org/10.1021/acs.jpcb.8b11609

Comments